Gujarat Themis gets $58 million private credit for deal
In short
Gujarat Themis secured $58 million in private credit for a Japanese acquisition. The company was founded in 1981 and says it was India’s first company to start making the anti-tuberculosis drug Rifampicin commercially.
This matters because the funding supports a cross-border deal. The report does not name the Japanese company or say when the purchase will happen.
What the reporting says
Gujarat Themis secured $58 million in private credit for a Japanese acquisition, according to a Business Standard summary. The company’s website says it was founded in 1981 and was India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin. The reporting does not name the Japanese target or say when the acquisition will close.
Why it matters
Gujarat Themis secured $58 million in private credit for a Japanese acquisition, according to the available summary. The company is identified as founded in 1981 and as India’s first commercial producer of Rifampicin, but the target, timing and other deal terms are not stated. The financing could affect the company’s expansion plans and debt profile.